Danube Pharmaceuticals

Danube Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the research and development of drugs and technologies for the treatment of ophthalmic and other related diseases. Its dnb-001 is a small molecule for the treatment of glaucoma. The company is also involved in the efficacy research of a novel oral therapy with a dual mechanism of action to reduce intraocular pressure (IOP) in patients with elevated IOP. The company was founded in 2005 and is headquartered in New York.